表紙
市場調査レポート

特殊な症例における拒絶反応抑制剤:世界市場

Anti-Rejection Drugs in Specialty Conditions: Global Market

発行 STIX Market Research 商品コード 305136
出版日 ページ情報 英文 179 Pages, 180 Tables
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
特殊な症例における拒絶反応抑制剤:世界市場 Anti-Rejection Drugs in Specialty Conditions: Global Market
出版日: 2014年06月06日 ページ情報: 英文 179 Pages, 180 Tables
概要

製薬会社は市場のシェアを拡大できるブロックバスター薬の開発を継続して追及しています。こうした企業は、移植や特殊な症例に用いられる拒絶反応抑制剤を将来の成長の機会ととらえています。米国が拒絶反応抑制剤の最大消費国です。

当レポートでは、世界の拒絶反応抑制剤の概要と、直近の市場データ、今後の予測とともに、抗体、mTOR阻害剤、代謝拮抗剤、コルチコステロイドなどのセグメント別の概要と地域別売上などをまとめています。

イントロダクション

エグゼクティブサマリー

概要

  • 拒絶反応抑制剤
  • 拒絶反応抑制剤のサプライヤー
  • 地域別動向
    • 南北アメリカ
    • 欧州
    • その他
  • 特殊な症例
  • 拒絶反応抑制剤の治療費
  • 拒絶反応抑制剤の長期的合併症
  • 技術的進歩
    • 手術における耐性
    • T細胞信号経路
    • ファーマコゲノミクス
    • 再生医療
    • 政府機関

抗体

  • 抗体の種類
  • 抗体サプライヤー

カルシニューリン阻害剤

  • カルシニューリン阻害剤の種類
  • カルシニューリン阻害剤製品
  • カルシニューリン阻害剤のサプライヤー
  • 地域別カルシニューリン阻害剤売上

mTOR阻害剤

  • mTOR阻害剤の種類
  • mTOR阻害剤製品
  • mTOR阻害剤のサプライヤー
  • 地域別mTOR阻害剤売上

代謝拮抗剤

  • 代謝拮抗剤の種類
  • 代謝拮抗剤のサプライヤー
  • 地域別代謝拮抗剤売上

コルチコステロイド

  • 特殊症例
  • コルチコステロイド製品
  • コルチコステロイドのサプライヤー
  • ジェネリックコルチコステロイドのサプライヤー
  • 地域別コルチコステロイド売上

移植

  • 移植における拒絶反応抑制剤
  • 世界の固形臓器移植活動
  • 固形臓器および組織における拒絶反応抑制剤の使用

炎症

  • 炎症における拒絶反応抑制剤
  • 慢性的炎症

腫瘍

  • 癌における拒絶反応抑制剤

心臓

  • 心臓における拒絶反応抑制剤

その他の症状

目次

Anti-Rejection Drugs for Specialty Drugs: Global Market predicts steady growth for the high-value products through 2018.

Pharmaceutical companies continue to pursue the blockbuster drug that will boost their market shares and profit margins. The companies are identifying which anti-rejection drugs can be adapted across lines of use beyond transplantation and into specialty conditions with potential growth opportunities.

"Novartis is a prime example of a company that has capitalized on the trend," states Norma Corbitt, a senior analyst with more than 25 years experience in pharmaceutical market research. "Expanding everolimus into oncology has netted the company a blockbuster product, Afinitor/Votubia. The product has also propelled mTOR inhibitors, which had been a relatively small market, to the forefront, passing up antimetabolites in sales and gaining on calcineurin inhibitors."

Report Highlights:

  • The report provides 2012 and 2013 market value data and 2018 forecasts for five classes of anti-rejection drugs. The report includes in-depth coverage of the individual drugs within a class, their specialty conditions, products (with patent expiries and new launches), suppliers, and regional activity. It also draws market conclusions about the five specialty conditions in which systemically-administered anti-rejection drugs are used.
  • In comparison to branded products, generic products remain a small market, yet managed care policies and national cost-containment measures that require less costly substitutes are promoting their growth. Nevertheless, physician preference and product efficacy should help branded products to withstand the onslaught of generic versions.
  • Four major suppliers generate most of the revenue with their well-established brands, international distribution networks, and aggressive marketing strategies. Niche and generic suppliers are entering the market, often through mergers and acquisitions, and are steadily encroaching on market shares of the major suppliers.
  • The U.S. is the largest consumer of anti-rejection drugs. Over the past two decades, however, regional activity has expanded exponentially, with the growth of transplantation programs, the number of patients suffering from life-threatening and debilitating other specialty conditions, major healthcare reforms, improved socioeconomic conditions, and changed cultural attitudes.

The 179-page report has 180 tables and is reasonably priced for the high quality of its content and costs $2850.

About Stix Market Research

Stix is a consulting and information evaluation organization of experts with experience in advanced technology market analyses and identification of business opportunities. The company provides factual evaluations of technologies, profiles of companies in the selected market sector, and advice on acquisitions, transitional business opportunities, and due diligence.

The purchase of an electronic copy of this report constitutes a contractual agreement between Stix and the purchaser. This report is intended for use solely by the purchaser. The report and its contents are not to be made available to other persons, autonomous divisions, foreign subsidiaries of the same company, or other companies. Reproduction of any material in this report is strictly forbidden without written permission of the publisher. In turn, Stix will regard the identity of report purchasers as strictly confidential.

The information developed in this report is as reliable as possible at the time of publication and is of a professorial nature. This information does not constitute managerial, legal, or accounting advice; neither should it serve as a corporate policy guide, a laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the report information or from its use.

Table of Contents

INTRODUCTION

  • REASONS FOR DOING STUDY
  • SCOPE OF STUDY
  • ANALYST'SCREDENTIALS
  • DISCLAIMER

EXECUTIVESUMMARY

  • SUMMARYTABLEA, GLOBAL ANTI-REJECTIONDRUGS MARKET SIZE, FOR SPECIALTYCONDITIONS, BY DRUG CLASS, 2013-2018

OVERVIEW

  • ANTI-REJECTION DRUG PRODUCTS
    • TABLE 1, GLOBAL ANTI-REJECTION DRUGS MARKET SIZE, BY PRODUCTTYPE, 2013-2018
  • ANTI-REJECTION DRUG SUPPLIERS
    • TABLE 2, GLOBAL ANTI-REJECTION DRUGS MARKET SIZE, BY SUPPLIER TYPE, 2013-2018
  • REGIONAL ANTI-REJECTION DRUGS ACTIVITY
    • TABLE 3, GLOBAL ANTI-REJECTION DRUGS MARKET SIZE, BY REGION, 2013-2018
    • AMERICAS
    • EUROPE
    • REST OF WORLD
      • ASIA/PACIFIC RIM
      • MIDDLE EAST
      • AFRICA
  • SPECIALTYCONDITIONS
  • TREATMENT COSTSOF ANTI-REJECTION DRUGS
  • LONG-TERM COMPLICATIONS OF ANTI-REJECTION DRUGS
  • TECHNOLOGICAL ADVANCES
    • OPERATIONAL TOLERANCE
      • MANIPULATION OF COSTIMULATORY PATHWAYS
      • TRANSFEROF HUMANREGULARTOY T CELLS
      • DENDRITICCELLS
      • BIOMARKERSIGNATURES
      • TARGETEDRADIATION
    • T-CELL SIGNALPATHWAYS
    • PHARMACOGENOMICS
    • REGENERATIVE MEDICINE
    • GOVERNMENTAL AGENCIES

ANTIBODIES

  • TYPES OF ANTIBODIES
    • TABLE 4, GLOBAL ANTIBODIES MARKETSIZE, FOR SPECIALTY CONDITIONS, BY TYPE, 2013-2018
    • MONOCLONAL ANTIBODIES
      • TABLE 5, GLOBAL MONOCLONAL ANTIBODIES MARKETSIZE, FOR SPECIALTYCONDITIONS, BY DRUG TYPE, 2013- 2018
      • BASILIXIMAB
        • Specialty Conditions
        • TABLE6, GLOBAL BASILIXIMAB MARKET SIZE, BY SPECIALTYCONDITION, 2013-2018
      • BELATACEPT
        • Specialty Conditions
        • TABLE7, GLOBAL BELATACEPT MARKET SIZE, BY SPECIALTYCONDITION,2013-2018
    • POLYCLONAL ANTIBODIES
    • TABLE 8, GLOBAL POLYCLONAL ANTIBODIES MARKETSIZE, FOR SPECIALTYCONDITIONS, BY DRUG TYPE, 2013- 2018
    • RABBIT-ATG
      • Specialty Conditions
        • TABLE9, GLOBAL RABBIT-ATG MARKET SIZE, BY SPECIALTYCONDITION, 2013-2018
      • Transplantation
        • TABLE 10, GLOBAL RABBIT-ATG MARKETSIZE, IN TRANSPLANTATION, 2013-2018
      • Miscellaneous Conditions
        • TABLE 11, GLOBAL RABBIT-ATG MARKET SIZE, IN MISCELLANEOUS CONDITIONS, 2013-2018
    • HORSE-ATG
      • Specialty Conditions
        • TABLE 12, GLOBAL HORSE-ATG MARKET SIZE, BY SPECIALTY CONDITION, 2013-2018
      • Transplantation
        • TABLE 13, GLOBALHORSE-ATG MARKETSIZE, IN TRANSPLANTATION, 2013-2018
      • Miscellaneous Conditions
        • TABLE 14, GLOBALHORSE-ATG MARKETSIZE, IN MISCELLANEOUS CONDITIONS, 2013-2018
      • ANTIBODY PRODUCTS
        • TABLE 15, GLOBAL ANTIBODIESMARKET SIZE, BY PRODUCT,2013-2018
      • THYMOGLOBULIN
        • TABLE 16, GLOBAL THYMOGLOBULIN MARKET SIZE, 2013-2018
      • SIMULECT
        • TABLE 17, GLOBAL SIMULECTMARKETSIZE, 2013-2018
      • ATG-FRESENIUSS
        • TABLE 18, GLOBAL ATG-FRESENIUS S MARKETSIZE, 2013-2018
      • NULOJIX
        • TABLE19, GLOBAL NULOJIXMARKET SIZE, 2013-2018
      • ATGAM
        • TABLE20, GLOBALATGAM MARKETSIZE,2013-2018
      • BIOSIMILAR PRODUCTS
  • ANTIBODY SUPPLIERS
    • TABLE 21, GLOBAL ANTIBODYSUPPLIERSMARKETSIZE, BY TYPE, 2013-2018
    • MAJOR ANTIBODYSUPPLIERS
      • TABLE 22, GLOBAL MAJOR ANTIBODYSUPPLIERS MARKET SIZE, 2013-2018
      • SANOFI
        • TABLE 23, GLOBAL SANOFI MARKETSIZE, 2013-2018
      • NOVARTIS
        • TABLE 24, GLOBAL NOVARTISMARKET SIZE, 2013-2018
    • NICHE ANTIBODYSUPPLIERS
      • TABLE 25, GLOBALNICHE ANTIBODYSUPLIERSMARKET SIZE, 2013-2018
      • NEOPHARM
        • TABLE 26, GLOBALNEOPHARMMARKET SIZE, 2013-2018
      • BRISTOL-MYERS SQUIBB
        • TABLE 27, GLOBAL BRISTOL-MYERS SQUIBBMARKETSIZE, 2013-2018
      • PFIZER
        • TABLE 28, GLOBALPFIZER MARKETSIZE, 2013-2018
    • REGIONAL ANTIBODYSALES
      • TABLE 29, GLOBAL ANTIBODYMARKET SIZE, BY REGION, 2013-2018
      • AMERICAS
        • TABLE 30, AMERICAS ANTIBODYMARKETSIZE, 2013-2018
      • EUROPE
        • TABLE 31, EUROPEANTIBODYMARKET SIZE, 2013-2018
      • REST OF WORLD
        • TABLE 32, ROW ANTIBODYMARKET SIZE, 2013-2018
    • INVESTIGATIONAL ANTIBODYPRODUCTS
      • ASPK 1240
      • BCX4208
      • OPN-305
      • STX-100
      • TOL101

CALCINEURIN INHIBITORS

  • TYPES OF CALCINEURIN INHIBITORS
    • TABLE33, GLOBALCALCINEURIN INHIBITORS MARKETSIZE, FOR SPECIALTYCONDITIONS, BY TYPE, 2013-2018
    • TACROLIMUS
      • SPECIALTY CONDITIONS
        • TABLE 34, GLOBAL TACROLIMUS MARKETSIZE, BY SPECIALTYCONDITION, 2013-2018
      • Transplantation
        • TABLE35, GLOBAL TACROLIMUS MARKETSIZE, IN TRANSPLANTATION, 2013-2018
      • Inflammation
        • TABLE 36, GLOBAL TACROLIMUS MARKET SIZE, IN INFLAMMATION, 2013-2018
    • CYCLOSPORINE
      • SPECIALTYCONDITIONS
        • TABLE37, GLOBAL CYCLOSPORINE MARKET SIZE, BY SPECIALTYCONDITION, 2013-2018
      • Transplantation
        • TABLE38, GLOBAL CYCLOSPORINEMARKET SIZE, IN TRANSPLANTATION, 2013-2018
      • Inflammation
        • TABLE39, GLOBALCYCLOSPORINE MARKET SIZE, IN INFLAMMATION, 2013-2018
      • Miscellaneous Conditions
        • TABLE 40, GLOBAL CYCLOSPORINE MARKETSIZE, IN MISCELLANEOUS CONDITIONS, 2013-2018
  • CALCINEURIN INHIBITOR PRODUCTS
    • TABLE41, GLOBAL CALCINEURIN INHIBITORS MARKETSIZE, BY PRODUCT,2013-2018
    • PROGRAFAND RELATEDBRANDS
      • TABLE42, GLOBAL PROGRAFAND RELATEDBRANDS MARKET SIZE, 2013-2018
    • NEORAL/SANDIMMUNE
      • TABLE43, GLOBAL NEORAL/SANDIMMUNEMARKETSIZE, 2013-2018
    • ENVARSUS
      • TABLE 44, GLOBAL ENVARUS MARKETSIZE, 2013-2018
    • GENERIC TACROLIMUS
      • TABLE45, GLOBAL GENERICTACROLIMUS MARKETSIZE, 2013-2018
    • GENERIC CYCLOSPORINE
      • TABLE46, GLOBAL GENERICCYCLOSPORINE MARKETSIZE, 2013-2018
  • CALCINEURIN INHIBITORS SUPPLIERS
    • TABLE47, GLOBAL CALCINEURIN INHIBITORS SUPPLIERS MARKET SIZE, BY TYPE, 2013-2018
    • MAJOR CALCINEURIN INHIBITORS SUPPLIERS
      • TABLE48, GLOBAL MAJOR CALCINEURIN INHIBITORS SUPPLIERSMARKET SIZE, 2013-2018
      • ASTELLAS
        • TABLE 49, GLOBAL ASTELLASMARKETSIZE, 2013-2018
      • NOVARTIS
        • TABLE50, GLOBAL NOVARTISMARKETSIZE, 2013-2018
    • NICHE CALCINEURIN INHIBITORS SUPPLIERS
      • VELOXISPHARMACEUTICALS A/S
        • TABLE51, GLOBALVELOXISMARKET SIZE, 2013-2018
    • GENERIC CALCINEURIN INHIBITORS SUPPLIERS
      • TABLE52, GLOBAL GENERICCALCINEURIN INHIBITORS SUPPLIERSMARKET SIZE, 2013-2018
        • ABBVIE
        • ACCORD HEALTHCARE
        • APOTEX
        • BIOCON
        • BOEHRINGERINGELHEIM
        • DR. REDDY'S
        • EMS-SIGMA
        • HANGZHOUZHONGMEI HUADON
        • NORTH CHINA PHARMACEUTICAL
        • PANACEA BIOTEC
        • RPG LIFE SCIENCES
        • SANDOZ
        • TEVA
        • ZHEJIANG HISUN PHARMACEUTICAL
  • REGIONAL CALCINEURIN INHIBITORS SALES
    • TABLE 53, GLOBAL CALCINEURIN INHIBITORS MARKET SIZE, BY REGION, 2013-2018
    • AMERICAS CALCINEURIN INHIBITORS SALES
      • TABLE 54, AMERICASCALCINEURIN INHBITORS MARKETSIZE, 2013-2018
    • EUROPECALCINEURIN INHIBITORS SALES
      • TABLE 55, EUROPECALCINEURIN INHBITORSMARKET SIZE, 2013-2018
    • REST OF WORLD CALCINEURIN INHIBITORS SALES
      • TABLE 56, ROW CALCINEURIN INHBITORMARKETSIZE, 2013-2018

MTOR INHIBITORS

  • TYPES OF MTOR INHIBITORS
    • TABLE57, GLOBAL MTOR INHIBITORS MARKET SIZE, FOR SPECIALTYCONDITIONS, BY TYPE, 2013-2018.
    • SIROLIMUS
      • SPECIALTY CONDITIONS
        • TABLE58, GLOBAL SIROLIMUS MARKETSIZE, BY SPECIALTYCONDITION, 2013-2018
      • Transplantation
        • TABLE59, GLOBAL SIROLIMUS MARKETSIZE, IN TRANSPLANTATION, 2013-2018
      • Inflammation
      • Oncology
      • Cardiology
        • TABLE 60, GLOBAL SIROLIMUS MARKETSIZE, IN CARDIOLOGY, 2013-2018
    • EVEROLIMUS
      • SPECIALTYCONDITIONS
        • TABLE61, GLOBAL EVEROLIMUS MARKETSIZE, BY SPECIALTY CONDITION, 2013-2018
      • Transplantation
        • TABLE62, GLOBAL EVEROLIMUS MARKETSIZE, IN TRANSPLANTATION, 2013-2018
      • Oncology
        • TABLE63, GLOBAL EVEROLIMUS MARKETSIZE, IN ONCOLOGY, 2013-2018
      • Cardiology
        • TABLE64, GLOBAL EVEROLIMUS MARKETSIZE, IN CARDIOLOGY, 2013-2018
  • MTOR INHIBITOR PRODUCTS
    • TABLE65, GLOBALMTOR INHIBITORS MARKET SIZE, BY PRODUCT,2013-2018
    • AFINITOR/VOTUBIA
      • TABLE66, GLOBAL AFINITOR/VOTUBIAMARKETSIZE, 2013-2018
    • RAPAMUNE
      • TABLE67, GLOBALRAPAMUNEMARKET SIZE, 2013-2018
    • CERTICAN/ZORTRESS
      • TABLE 68, GLOBAL CERTICAN/ZORTRESS MARKETSIZE, 2013-2018
    • GENERIC SIROLIMUS
      • TABLE 69, GLOBAL GENERIC SIROLIMUS MARKETSIZE, 2013-2018
    • GENERIC EVEROLIMUS
      • TABLE 70, GLOBAL GENERIC EVEROLIMUS MARKETSIZE, 2013-2018
  • MTOR INHIBITORSUPPLIERS
    • TABLE 71, GLOBAL MTOR INHIBITORSUPPLIERSMARKETSIZE, BY TYPE, 2013-2018
    • MAJOR MTOR INHIBITORS SUPPLIERS
    • TABLE 72, GLOBAL MAJOR MTOR INHIBITORS SUPPLIERS MARKET SIZE, 2013-2018
      • NOVARTIS
        • TABLE73, GLOBAL NOVARTISMARKETSIZE, 2013-2018
      • PFIZER
      • TABLE74, GLOBAL PFIZER MARKETSIZE, 2013-2018
    • GENERIC MTOR INHIBITORS SUPPLIERS
      • TABLE 75, GLOBALGENERICMTOR INHIBITORS SUPPLIERS MARKET SIZE, 2013-2018
      • BIOCON
      • HANGZHOU ZHONGMEI HUADONGPHARMACEUTICAL
      • PANACEA BIOTEC
      • ZYDUS PHARMACEUTICALS USA
  • REGIONALMTOR INHIBITORS SALES
    • TABLE 76, GLOBALMTOR INHIBITORS MARKETSIZE, BY REGION, 2013-2018
    • AMERICASMTOR INHIBITORS SALES
      • TABLE 77, AMERICASMTOR INHIBITORS MARKET SIZE, 2013-2018
    • EUROPE MTOR INHIBITORS SALES
      • TABLE 78, EUROPEMTOR INHIBITORSMARKET SIZE, 2013-2018
    • REST OF WORLD MTOR INHIBITORS SALES
      • TABLE 79, ROW MTOR INHIBITORS MARKET SIZE, 2013-2018

ANTIMETABOLITES

  • TYPES OF ANTIMETABOLITE DRUGS
    • TABLE80, GLOBAL ANTIMETABOLITES MARKETSIZE, FOR SPECIALTYCONDITIONS, BY TYPE, 2013-2018
    • MYCOPHENOLATE
      • TABLE81, GLOBAL MYCOPHENOLATE MARKET SIZE, FOR SPECIALTYCONDITIONS, BY FORMAT, 2013-2018
    • MYCOPHENOLATE MOFETIL (MMF)
      • Specialty Conditions
        • TABLE82, GLOBAL MMF MARKETSIZE, BY SPECIALTYCONDITION, 2013-2018
      • Transplantation
        • TABLE83, GLOBALMMF MARKETSIZE, IN TRANSPLANTATION, 2013-2018
      • Inflammation
        • TABLE84, GLOBALMMF MARKETSIZE, IN INFLAMMATION, 2013-2018
    • MYCOPHENOLATE SODIUM (MPS)
      • Specialty Conditions
        • TABLE85, GLOBAL MPS MARKET SIZE, BY SPECIALTY CONDITION, 2013-2018
    • MIZORIBINE
      • SPECIALTYCONDITIONS
        • TABLE86, GLOBAL MIZORIBINE MARKET SIZE, BY SPECIALTY CONDITION, 2013-2018
      • Transplantation
        • TABLE87, GLOBAL MIZORIBINE MARKETSIZE, IN TRANSPLANTATION, 2013-2018
      • Inflammation
        • TABLE88, GLOBAL MIZORIBINE MARKETSIZE, IN INFLAMMATION, 2013-2018
    • AZATHIOPRINE
      • SPECIALTYCONDITIONS
        • TABLE 89, GLOBALAZATHIOPRINE MARKET SIZE, BY SPECIALTYCONDITION, 2013-2018
      • Transplantation
        • TABLE 90, GLOBAL AZATHIOPRINE MARKETSIZE, IN TRANSPLANTATION, 2013-2018
      • Inflammation
        • TABLE 91, GLOBAL AZATHIOPRINE MARKETSIZE, IN INFLAMMATION, 2013-2018
      • ANTIMETABOLITE PRODUCTS
        • TABLE92, GLOBAL ANTIMETABOLITESMARKETSIZE, BY PRODUCT,2013-2018
      • CELLCEPT
        • TABLE93, GLOBAL CELLCEPTMARKETSIZE, 2013-2018
      • MYFORTIC
        • TABLE 94, GLOBALMYFORTICMARKETSIZE, 2013-2018
      • BREDININ
        • TABLE95, GLOBAL BREDININMARKET SIZE, 2013-2018
      • IMURAN
        • TABLE 96, GLOBAL IMURAN MARKETSIZE, 2013-2018
      • GENERICMMF
        • TABLE 97, GLOBAL GENERICMMF MARKETSIZE, 2013-2018
      • GENERIC MPS
        • TABLE98, GLOBAL GENERIC MPS MARKET SIZE, 2013-2018
      • GENERIC AZATHIOPRINE
        • TABLE99, GLOBAL GENERICAZATHIOPRINE MARKET SIZE, 2013-2018
  • ANTIMETABOLITE SUPPLIERS
    • TABLE100, GLOBAL ANTIMETABOLITE SUPPLIERS MARKET SIZE, BY TYPE, 2013-2018
    • MAJOR ANTIMETABOLITE SUPPLIERS
      • TABLE101, GLOBAL MAJOR ANTIMETABOLITE SUPPLIERS MARKET SIZE, 2013-2018
      • F. HOFFMANN-LA ROCHE
        • TABLE 102, GLOBAL F. HOFFMAN-LA ROCHE MARKET, SIZE, 2013-2018
      • NOVARTIS
        • TABLE103, GLOBAL NOVARTISMARKETSIZE, 2013-2018
    • NICHE ANTIMETABOLITE SUPPLIERS
      • TABLE 104, GLOBAL NICHE ANTIMETABOLITE SUPPLIERS MARKET SIZE, 2013-2018
      • ASAHI KASEI
      • ASPEN PHARMACARE
      • EISAI
      • PROMETHEUS
    • GENERIC ANTIMETABOLITE SUPPLIERS
      • TABLE 105, GLOBAL GENERIC ANTIMETABOLITE SUPPLIERS MARKET SIZE, 2013-2018
      • ACCORD HEALTHCARE
      • ACTAVIS
      • APOTEX
      • BIOCON
      • BOEHRINGERINGELHEIM
      • HANGZHOUZHONGMEI HUADONG
      • HERBERTJ. PASSAUER
      • MYLAN
      • NAVAMEDIC
      • NORTH CHINA PHARMACEUTICAL
      • PANACEA BIOTEC
      • SALIX PHARMACEUTICALS, INC
      • SANDOZ
      • STRIDES ACROLAB,LTD
      • TEVA PHARMACEUTICALS INDUSTRIES, LTD
      • ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
      • ZYDUS PHARMACEUTICALS USA, INC
  • REGIONAL ANTIMETABOLITES SALES
    • TABLE 106 GLOBAL ANTIMETABOLITESMARKETSIZE, BY REGION, 2013-2018
    • AMERICAS ANTIMETABOLITES SALES
      • TABLE 107, AMERICASANTIMETABOLITESMARKETSIZE 2013-2018
    • EUROPE ANTIMETABOLITES SALES
      • TABLE 108, EUROPEANTIMETABOLITES MARKETSIZE, 2013-2018
    • REST OF WORLDANTIMETABOLITES SALES
      • TABLE 109, ROW ANTIMETABOLITESMARKETSIZE 2013-2018

CORTICOSTEROIDS

  • SPECIALTYCONDITIONS
    • TABLE 110, GLOBAL CORTICOSTEROIDSMARKETSIZE, BY SPECIALTYCONDITION, 2013-2018
    • TRANSPLANTATION
      • TABLE 111, GLOBAL CORTICOSTEROIDSMARKETSIZE, IN TRANSPLANTATION, 2013-2018
    • INFLAMMATION
      • TABLE 112, GLOBAL CORTICOSTEROIDSMARKETSIZE, IN INFLAMMATION, 2013-2018
    • MISCELLANOUS CONDITIONS
      • TABLE 113, GLOBAL CORTICOSTEROIDSMARKET SIZE, IN MISCELLANEOUS CONDITIIONS, 2013-2018
  • CORTICOSTEROID PRODUCTS
    • TABLE 114, GLOBAL CORTICOSTEROIDS MARKETSIZE, BY PRODUCT,2013-2018
    • MEDROL
      • TABLE 115, GLOBALMEDROL MARKETSIZE, 2013-2018
    • GENERIC CORTICOSTEROID PRODUCTS.
      • TABLE 116, GLOBAL CORTICOSTEROIDSMARKETSIZE, 2013-2018
  • CORTICOSTEROIDS SUPPLIERS
    • TABLE 117, GLOBAL CORTICOSTEROIDS SUPPLIERS MARKET SIZE, BY TYPE, 2013-2018
    • MAJOR CORTICOSTEROIDS SUPPLIERS
    • PFIZER
      • TABLE 118, GLOBAL PFIZER MARKET SIZE, 2013-2018
    • NICHE CORTICOSTEROIDS SUPPLIERS
      • TABLE 119, GLOBAL NICHE CORTICOSTEROIDS SUPPLIERS MARKET SIZE, 2013-2018
    • ALLIANCEPHARMA
    • FUGI PHARMA
    • RECORDATI
  • GENERIC CORTICOSTEROIDS SUPPLIERS
    • TABLE 120, GLOBAL GENERICCORTICOSTEROIDS SUPPLIERS MARKET SIZE, 2013-2018
  • REGIONALCORTICOSTEROIDS SALES
    • TABLE 121, GLOBAL CORTICOSTEROIDSMARKETSIZE, BY REGION, 2013-2018
  • AMERICAS CORTICOSTERIODS SALES
    • TABLE 122, AMERICAS CORTICOSTEROIDSMARKETSIZE, 2013-2018
  • EUROPE CORTICOSTEROIDS SALES
    • TABLE 123, EUROPECORTICOSTEROIDS MARKETSIZE, 2013-2018
  • REST OF WORLD CORTICOSTEROIDS SALES
    • TABLE 124, ROW CORTICOSTEROIDSMARKET SIZE, 2013-2018

TRANSPLANTATION

  • ANTI-REJECTION DRUGS IN TRANSPLANTATION
    • TABLE 125, GLOBAL TRANSPLANTATION DRUGS MARKET SIZE, FOR ANTI-REJECTION DRUGS, BY REGIMEN, 2013-2018
    • INDUCTION IMMUNOTHERAPY
      • TABLE 126, GLOBAL INDUCTION REGIMENS MARKET SIZE, 2013-2018
    • MAINTENANCE IMMUNOTHERAPY
      • TABLE 127, GLOBAL MAINTENANCE REGIMENS MARKET SIZE, 2013-2018
    • REJECTIONEPISODES
      • HYPER-ACUTE REJECTION
      • ACUTE REJECTION
      • CHRONIC REJECTION
  • GLOBAL SOLID-ORGAN TRANSPLANTATION ACTIVITY
    • FIGURE 1, GLOBAL SOLID-ORGAN TRANSPLANTATION ACTIVITIES, 2012
    • GLOBAL SOLID-ORGAN TRANSPLANT RECIPIENTS
      • TABLE 128, GLOBAL SOLID-ORGAN TRANSPLANT RECIPIENTS, 2013-2018
    • REGIONALSOLID-ORGAN TRANSPLANT RECIPIENTS
      • TABLE 129, REGIONAL SOLID-ORGAN TRANSPLANT RECIPIENTS, 2013
    • AMERICAS
    • EUROPE
    • REST OF WORLD
      • Asia/Pacific Rim
      • Middle East
      • Africa
    • GLOBAL SOLID-ORGAN TRANSPLANT SURVIVORS
    • TABLE 130, GLOBAL SOLID-ORGAN TRANSPLANT SURVIVORS, 2013-2018
  • ANTI-REJECTION DRUGS USAGE IN SOLID ORGANS AND TISSUE
    • KIDNEY
      • TABLE 131, GLOBALKIDNEY TRANSPLANTRECIPIENTS, 2013-2018
        • TABLE 132, REGIONAL KIDNEY TRANSPLANT RECIPIENTS, 2013
      • INDUCTIONREGIMENS
        • TABLE 133, INDUCTION REGIMENSIN KIDNEY TRANSPLANT RECIPIENTS, 2013
      • None
      • Basiliximab
      • Rabbit-ATG
      • Horse-ATG
      • Combinations
      • BASELINEMAINTENANCEREGIMENS
        • TABLE 134, BASELINEMAINTENANCE REGIMENS IN KIDNEY TRANSPLANTRECIPIENTS, 2013
      • Antibodies
      • Calcineurin Inhibitors
      • Antimetabolites
      • MTOR Inhibitors
      • Corticosteroids
      • SEQUENTIAL MAINTENANCEREGIMENS
        • TABLE 135, SEQUENTIAL MAINTENANCE REGIMENSIN KIDNEYTRANSPLANT RECIPIENTS, 2013
      • Triple-Dose Protocols
      • Dual-Dose Protocols
      • Monotherapy
    • LIVER
      • TABLE 136, GLOBAL LIVER TRANSPLANT RECIPIENTS, 2013-2018
      • TABLE 137, REGIONALLIVER TRANSPLANT RECIPIENTS, 2013
      • INDUCTION REGIMENS
      • TABLE 138, INDUCTION REGIMENSIN LIVER TRANSPLANT RECIPIENTS, 2013
        • None
        • Basiliximab
        • Rabbit-ATG
        • Horse-ATG
      • BASELINEMAINTENANCE REGIMENS
        • TABLE 139, BASELINEMAINTENANCE REGIMENS IN LIVER TRANSPLANT RECIPIENTS, 2013
      • Antibodies
      • Calcineurin Inhibitors
      • Antimetabolites
      • MTOR Inhibitors
      • Corticosteroids
    • SEQUENTIAL MAINTENANCEREGIMENS
      • TABLE 140, SEQUENTIAL MAINTENANCE REGIMENSIN LIVER TRANSPLANT RECIPIENTS, 2013
      • Triple-Dose Protocols
      • Dual-Dose Protocols
      • Monotherapy
    • HEART
      • TABLE 141, GLOBAL HEARTTRANSPLANT RECIPIENTS, 2013-2018
      • TABLE 142, REGIONALHEART TRANSPLANT RECIPIENTS, 2013
      • INDUCTIONREGIMENS
      • TABLE 143, INDUCTIONREGIMENSIN HEART TRANSPLANT RECIPIENTS, 2013
        • None
        • Basiliximab
        • Rabbit-ATG
        • Horse-ATG
      • BASELINE MAINTENANCEREGIMENS
      • TABLE 144, BASELINEMAINTENANCE REGIMENSIN HEART TRANSPLANT RECIPIENTS, 2013
      • Antibodies
      • Calcineurin Inhibitors
      • Antimetabolites
      • MTOR Inhibitors
      • Corticosteroids
    • SEQUENTIAL MAINTENANCEREGIMENS
      • TABLE 145, SEQUENTIAL MAINTENANCE REGIMENSIN HEARTTRANSPLANT RECIPIENTS, 2013
      • Triple-Dose Protocols
      • Dual-Dose Protocols
      • Monotherapy
    • LUNG
      • TABLE 146, GLOBAL LUNGTRANSPLANT RECIPIENTS, 2013-2018
      • TABLE 147, REGIONALLUNG TRANSPLANT RECIPIENTS, 2013
      • INDUCTIONREGIMENS
      • TABLE 148, INDUCTIONREGIMENSIN LUNG TRANSPLANT RECIPIENTS, 2013
        • None
        • Basiliximab
        • Rabbit-ATG
        • Horse-ATG
      • BASELINEMAINTENANCE REGIMENS
      • TABLE 149, BASELINEMAINTENANCE REGIMENSIN LUNG TRANSPLANT RECIPIENTS, 2013
        • Antibodies
        • Calcineurin Inhibitors
        • Antimetabolites
        • MTOR Inhibitors
        • Corticosteroids
      • SEQUENTIAL MAINTENANCE REGIMENS
        • TABLE 150, SEQUENTIAL MAINTENANCE REGIMENSIN LUNGTRANSPLANT RECIPIENTS, 2013
        • Triple-Dose Protocols
        • Dual-Dose Protocols
        • Monotherapy
      • PANCREAS
        • TABLE 151, GLOBAL PANCREASTRANSPLANT RECIPIENTS, 2013-2018
        • TABLE 152, REGIONALPANCREASTRANSPLANT RECIPIENTS, 2013
        • INDUCTIONREGIMENS
        • TABLE 153, INDUCTIONREGIMENSIN PANCREAS TRANSPLANT RECIPIENTS, 2013
          • None
          • Basiliximab
          • Rabbit-ATG
          • Horse-ATG
          • Combinations
        • BASELINE MAINTENANCE REGIMENS
        • TABLE 154, BASELINEMAINTENANCE REGIMENSIN PANCREASTRANSPLANT RECIPIENTS, 2013
          • Antibodies
          • Calcineurin Inhibitors
          • Antimetabolites
          • MTOR Inhibitors
          • Corticosteroids
        • SEQUENTIAL MAINTENANCE REGIMENS
      • TABLE 155, SEQUENTIAL MAINTENANCE REGIMENSIN PANCREAS TRANSPLANT RECIPIENTS, 2013
        • Triple-Dose Protocols
        • Dual-Dose Protocols
        • Monotherapy
      • INTESTINE
        • TABLE 156, GLOBAL INTESTINETRANSPLANT RECIPIENTS, 2013-2018
        • TABLE 157, REGIONAL INTESTINE TRANSPLANT RECIPIENTS, 2013
        • INDUCTIONREGIMENS
        • TABLE 158, INDUCTIONREGIMENSIN INTESTINE TRANSPLANT RECIPIENTS, 2013
          • None
          • Basiliximab
          • Rabbit-ATG
          • Horse-ATG
          • Combinations
      • BASELINEMAINTENANCE REGIMENS
      • TABLE 159, BASELINEMAINTENANCE REGIMENS IN INTESTINE TRANSPLANTRECIPIENTS, 2013
        • Antibodies
        • Calcineurin Inhibitors
        • Antimetabolites
        • MTOR Inhibitors
        • Corticosteroids
      • SEQUENTIAL MAINTENANCE REGIMENS
        • TABLE 160, SEQUENTIAL MAINTENANCE REGIMENSIN INTESTINE TRANSPLANTRECIPIENTS, 2013
        • Triple-Dose Protocols
        • Dual-Dose Protocols
        • Monotherapy
  • TISSUE
    • EYE
      • Cornea
      • Sclera
      • Retina
    • BLOOD STEM CELLS
    • MUSCULOSKELETAL COMPONENTS
    • HEART VALVES/BLOOD VESSELS
    • PANCREATIC ISLETS

INFLAMMATION

  • ANTI-REJECTION DRUGS IN INFLAMMATION
    • TABLE 161, GLOBAL INFLAMMATION MARKET SIZE, FOR ANTI-REJECTION DRUGS, BY DRUG CLASS, 2013-2018
    • ANTIBODIES
    • CALCINEURIN INHIBITORS
      • TABLE 162, GLOBAL INFLAMMATION MARKET SIZE, FOR CALCINEURIN INHIBITORS, BY TYPE, 2013-2018
      • TACROLIMUS
      • TABLE 163, GLOBAL INFLAMMATION MARKET SIZE, FOR TACROLIMUS, 2013-2018
      • CYCLOSPORINE
      • TABLE 164, GLOBAL INFLAMMATION MARKET SIZE, FOR CYCLOSPORINE, 2013-2018
    • ANTIMETABOLITES
      • TABLE 165, GLOBAL INFLAMMATION MARKET SIZE, FOR ANTIMETABOLITES, BY TYPE, 2013-2018
      • MYCOPHENOLATE MOFETIL
      • TABLE 166, GLOBAL INFLAMMATION MARKET SIZE, FOR MYCOPHENOLATE MOFETIL, 2013-2018
      • MIZORIBINE
      • TABLE 167, GLOBAL INFLAMMATION MARKET SIZE, FOR MIZORIBINE, 2013-2018
      • AZATHIOPRINE
      • TABLE 168, GLOBAL INFLAMMATION MARKET SIZE, FOR AZATHIOPRINE, 2013-2018
    • MTOR INHIBITORS
      • CORTICOSTEROIDS
      • TABLE 169, GLOBAL INFLAMMATION MARKET SIZE, FOR CORTICOSTEROIDS, 2013-2018
  • CHRONICINFLAMMATORY CONDITIONS
    • MAJOR CHRONICINFLAMMATORY CONDITIONS
      • TABLE 170, MAJOR CHRONIC INFLAMMATORY CONDITIONS WORLDWIDE, 2013
      • HEPATITIS
      • ARTHRITIS
      • ASTHMA
      • PSORIASIS
    • OTHER CHRONICINFLAMMATORY CONDITIONS
      • TABLE 171, MAJOR CHRONIC INFLAMMATORY CONDITIONS WORLDWIDE, 2013
      • SYSTEMICLUPUS ERYTHEMATOSUS
      • INFLAMMATORY BOWEL DISEASE
      • MULTIPLE SCLEROSIS
      • MYASTHENIA GRAVIS
      • VASCULITIS

ONCOLOGY

  • ANTI-REJECTION DRUGS IN ONCOLOGY
    • TABLE 172, GLOBAL ONCOLOGYMARKET SIZE, FOR ANTI-REJECTION DRUGS, BY DRUG CLASS, 2013-2018
    • ANTIBODIES
    • CALCINEURIN INHIBITORS
    • ANTIMETABOLITES
    • MTOR INHIBITORS
      • TABLE 173, GLOBAL ONCOLOGY MARKET SIZE, FOR MTOR INHIBITORS, BY TYPE, 2013-2018
      • SIROLIMUS
      • EVEROLIMUS
      • TABLE 174, GLOBAL ONCOLOGY MARKET SIZE, FOR EVEROLIMUS, 2013-2018
      • CORTICOSTEROIDS

CARDIOLOGY

  • ANTI-REJECTION DRUGS IN CARDIOLOGY
    • TABLE 175, GLOBAL CARDIOLOGY MARKET SIZE, FOR ANTI-REJECTION DRUGS, BY DRUG CLASS, 2013-2018
    • MTOR INHIBITORS
    • TABLE 176, GLOBAL CARDIOLOGY MARKET SIZE, FOR MTOR INHIBITORS, BY TYPE, 2013-2018
    • SIROLIMUS
    • TABLE 177, GLOBAL CARDIOLOGY MARKET SIZE, FOR SIROLIMUS, 2013-2018
    • EVEROLIMUS
    • TABLE 178, GLOBAL CARDIOLOG MARKET SIZE, IN EVEROLIMUS, 2013-2018

MISCELLANEOUSCONDITIONS

  • ANTI-REJECTION DRUGS IN MISCELLANEOUS CONDITIONS
    • TABLE 179, GLOBAL MISCELLANEOUS CONDITIONS MARKET SIZE, FOR ANTI-REJECTIONDRUGS, BY DRUG CLASS,2013-2018
    • ANTIBODIES
    • TABLE 180, GLOBAL MISCELLANEOUS CONDITIONS MARKET SIZE FOR ANTIBODIES, 2013-2018
    • RABBIT-ATG
    • TABLE 181, GLOBAL MISCELLANEOUS CONDITIONS MARKET SIZE FOR RABBIT-ATG, 2013-2018
    • HORSE-ATG
    • TABLE 182, GLOBAL MISCELLANEOUS CONDITIONS MARKET SIZE FOR HORSE-ATG, 2013-2018
    • CALCINEURIN INHIBITORS
    • TABLE 183, GLOBAL MISCELLANEOUS CONDITIONS MARKET SIZE, FOR CALCINEURIN INHIBITORS, 2013-2018
    • CORTICOSTEROIDS
    • TABLE 184, GLOBAL MISCELLANEOUS CONDITIONS MARKET SIZE, FOR CORTICOSTEROIDS IN, 2013-2018
Back to Top